NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues rose 5 percent, and it swung from a loss to a profit.

The San Diego-based firm missed analysts' consensus estimate, and its shares plunged 21 percent to $32.99 in after-hours trade — though its shares were trading at $35.23 in early Wednesday trade. The shortfall was due to a few issues, including a quality control issue related to sequencing reagent kits that could impact Illumina's Q4 revenues as well.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.